← FDA DRUG APPROVALS

FDA ANDA · ANDA071644

IBUPROFEN

Sponsor: PH HEALTH

APPLICATION
ANDA071644
TYPE
ANDA
ORIGINAL APPROVAL
1988-02-01
LATEST ACTION
2019-07-22
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

IBUPROFENDiscontinued
IBUPROFEN 400MG · TABLET · ORAL

Approval history

2019-07-22Labeling · Supplement 11 · standardAP
2016-05-09Labeling · Supplement 10 · standardAP
1991-10-18Manufacturing (CMC) · Supplement 8AP
1991-10-18Manufacturing (CMC) · Supplement 6AP
1991-10-18Manufacturing (CMC) · Supplement 7AP
1991-06-12Manufacturing (CMC) · Supplement 3AP
1989-09-19Bioequivalence · Supplement 5AP
1988-06-17Manufacturing (CMC) · Supplement 2AP
1988-06-17Manufacturing (CMC) · Supplement 1AP
1988-02-01OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →